post myocardial infarction

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathNon fatal MI

anti inflammatory drugs  

not classified  
CANTOS, 2017      NCTcanakinumab placeboLow risk of bias remark

antiarrythmic drugs  

not classified  
BASIS, 1990   class I drugscontrol -
CAST I, 1991    NCTplaceboLow risk of bias -
Julian, 1982     d,l sotalolplaceboLow risk of bias -
amiodarone  
Navarro-Lopez, 1993   early amiodaronecontrolnegative-52%
BASIS, 1990   early amiodaronecontrolsuggesting-59%
Hockings, 1987     early amiodaroneplaceboLow risk of bias negative94%
Ceremuzynski, 1992   early amiodaroneplaceboLow risk of bias negative-37%
CAMIAT , 1991   early amiodaroneplaceboLow risk of bias negative-18%
Azimilide  
ALIVE, 2004       azimilideplaceboLow risk of bias -
dofetilide  
DIAMOND MI, 1997   dofetilideplaceboLow risk of bias -
moricizine  
CAST II (late treatment), 1992   moricizineplaceboLow risk of bias -
CAST II (early treatment), 1992   moricizineplaceboLow risk of bias -

anticoagulant  

not classified  
Sixty Plus reinfarction Study, 1980   any anticoagulantplaceboLow risk of bias -
German-Austrian Study Group (oac vs pbo), 1980   phenprocoumonplaceboLow risk of bias negative14%
EPSIM, 1982   any anticoagulantaspirinnegative-10%
German-Austrian Study Group (oac vs asp), 1980   phenprocoumonaspirinLow risk of bias negative 43%
coumadin  
ASPECT-2 (coumadin+ASA vs ASA), 2002     coumadincontrol (on top of aspirin)negative -42%
ASPECT, 1994   coumadinplaceboLow risk of bias suggesting -10%
ASPECT-2 (coumadin alone), 2002     coumadinaspirinsuggesting-72%
warfarin  
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 2%
CARS (warafrin 3mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias suggesting-27%
LoWASA, 2004     warfarincontrol (on top of aspirin)Risk of bias suggesting -5%
CARS (warfarin 1mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias negative 3%
WARIS II (warfarin+ASA), 2002     warfarincontrol (on top of aspirin)suggesting -2%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative -67%
APRICOT-2, 2002     warfarincontrol (on top of aspirin)suggesting∞%
WARIS, 1999   warfarincontrol (on top of aspirin)Low risk of bias -
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias suggesting-100%
WARIS II (warfarin alone), 2002     warfarinaspirinsuggesting 3%

antioxydants  

not classified  
ARISE, 2007      NCTsuccinobucolplaceboLow risk of bias -

antiplatelets drug  

aspirin  
JAMIS, 1999     aspirinplacebosuggesting18%-73%
PARIS, 1980   aspirinplaceboLow risk of bias negative-18%-30%
GAMIS, 1980   aspirinplaceboLow risk of bias negative-18%-29%
AMIS, 1980    NCTaspirinplaceboLow risk of bias suggesting11%-22%
Vogel, 1979   aspirinplaceboLow risk of bias suggesting-32%-53%
CDPA, 1976   aspirinplaceboLow risk of bias negative-30%-11%
Cardiff I, 1974   aspirinplaceboLow risk of bias negative-26%
Cardiff II, 1979   aspirinplaceboLow risk of bias negative-17%
clopidogrel  
CAPRIE, 1996     clopidogrelaspirinLow risk of bias -
dipyridamol  
PARIS, 1980   dipyridamol + aspirinplaceboLow risk of bias negative
PARIS-II, 1986   dipyridamol + aspirinplaceboLow risk of bias negative
PARIS, 1980   dipyridamol + aspirinaspirinLow risk of bias negative
ticagrelor  
PEGASUS 60mg, 2015        NCTticagrelorplacebo (on top aspirin)secondary preventionLow risk of bias suggesting -11%
PEGASUS 90mg, 2015        NCTticagrelorplacebo (on top aspirin)secondary preventionLow risk of bias suggesting 0%
vorapaxar  
TRA-2P TIMI 50, 2012        NCTvorapaxarplacebo (on top aspirin)secondary preventionLow risk of bias suggesting -4%

antithrombotics  

dabigatran  
REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative

calcium channel blockers  

diltiazem  
MDPIT, 1988   diltiazemplaceboLow risk of bias negative0%
nifedipine  
MI study group, 1979   nifedipine -
SPRINT I, 1988   nifedipineplaceboLow risk of bias negative1%
SPRINT II, 1993   nifedipineplaceboLow risk of bias negative16%
verapamil  
DAVIT I, 1984   verapamilplaceboLow risk of bias -
DAVIT II, 1990   verapamilplaceboLow risk of bias negative-18%
CRIS, 1996     verapamilplaceboLow risk of bias negative6%
Danish study, 1984     verapamilplaceboLow risk of bias negative

cholesterol lowering intervention  

atorvastatin  
TNT, 2005            NCTatorvastatin high doseatorvastatinsecondary preventionLow risk of bias conclusive 1%-21%
Vascular basis, 2005     atorvastatin high doselovastatinsecondary preventionExploratory negative∞%
SAGE, 2007     atorvastatin high dosepravastatinsecondary preventionExploratory suggesting-67%-6%
REVERSAL, 2004     atorvastatin high dosepravastatinsecondary preventionExploratory negative
IDEAL, 2005        NCTatorvastatin high dosesimvastatinsecondary preventionRisk of bias suggesting -2%-17%
bezafibrate  
BIP, 2000       bezafibrateplacebosecondary preventionLow risk of bias negative6%-13%
BECAIT, 1996     bezafibrateplacebosecondary preventionExploratory suggesting∞%
diet  
Tuttle, 2008     low fat dietmediterranean-style dietRisk of bias -
ezetimibe  
IMPROVE-IT, 2014      NCTezetimibeplacebo (on top statins) early initiation Low risk of bias conclusive-1%
gemfibrozil  
VA-HIT, 1999      NCTgemfibrozilplaceboLow risk of bias suggesting-10%-20%
niacin  
Carlson (Stockholm), 1977   clofibtate+niacinplacebosecondary preventionRisk of bias suggesting-26%-31%
pravastatin  
CARE, 1996       pravastatinplacebosecondary preventionLow risk of bias conclusive-8%-22%
LIPID, 1998         pravastatinplacebosecondary preventionLow risk of bias conclusive-22%
PACT, 2004     pravastatinplacebosecondary preventionLow risk of bias negative-36%7%
simvastatin  
4S, 1994   simvastatinplacebosecondary preventionLow risk of bias conclusive-29%-33%

omega-3 fatty acids  

not classified  
OMEGA, 2009      NCTomega-3 Fatty acidscontrolRisk of bias negative 23%

secondary prevention  

aspirin  
CDPA, 1976   aspirinplaceboLow risk of bias negative-30%-11%
Cardiff I, 1974   aspirinplaceboLow risk of bias negative-26%
Vogel, 1979   aspirinplaceboLow risk of bias suggesting-32%-53%
AMIS, 1980    NCTaspirinplaceboLow risk of bias suggesting11%-22%
GAMIS, 1980   aspirinplaceboLow risk of bias negative-18%-29%
PARIS, 1980   aspirinplaceboLow risk of bias negative-18%-30%
JAMIS, 1999     aspirinplacebosuggesting18%-73%
Cardiff II, 1979   aspirinplaceboLow risk of bias negative-17%
clopidogrel  
CAPRIE, 1996     clopidogrelaspirinLow risk of bias -
dipyridamol  
PARIS, 1980   dipyridamol + aspirinplaceboLow risk of bias negative
PARIS-II, 1986   dipyridamol + aspirinplaceboLow risk of bias negative
PARIS, 1980   dipyridamol + aspirinaspirinLow risk of bias negative